Your search for supplemental oxygen returned 75 results

Significant reductions seen in RSV-related infections, RSV-related hospitalizations for three monoclonal antibodies versus placebo

The studies evaluated routine clinical practice data from more than 800 hospitals in the US.

Actemra (tocilizumab) is an interleukin-6 receptor antagonist.

Kineret is an interleukin-1 receptor antagonist.

High-dose inhaled nitric oxide linked to more days free from oxygen supplementation, shorter ICU and hospital length of stay

Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity

Rates of severe disease low for high-risk patients with mild-to-moderate COVID-19 treated with antispike monoclonal antibodies

The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.

Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.

The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.